SEARCH

SEARCH BY CITATION

References

  • 1
    Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142: 1314-1323 e1.
  • 2
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM. Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 3
    Poordad F, McCone JJr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 4
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM,ZeuzemS et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 5
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S. et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  • 6
    Annonymous. Package insert Victrelis. Whitehouse Station, NJ; 2011.
  • 7
    Anonymous. Package insert Incivek. Cambridge, MA; 2011.
  • 8
    Liu J, Jadhav P, Amur S, Fleischer R, Hammerstrom T, Lewis L, et al. Response guided telaprevir therapy in prior relapsers: The role of bridging data from treatment-naive and experienced subjects. HEPATOLOGY 2013; 57: 897-902.
  • 9
    Florian J, Jadhav P, Amur S, Ayala R, Harrington P, Mishra P, et al. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naive and experienced subjects. HEPATOLOGY 2013; 57: 903-907.
  • 10
    Center for Drug Evaluation and Research. 2012. Accessed 2012, at www.fda.gov/drugs/scienceresearch
  • 11
    Jadhav PR, Neal L, Florian J, Chen Y, Naeger L, Robertson S, et al. Antiviral Information Management System (AIMS): a prototype for operational innovation in drug development. J Clin Pharmacol 2010; 50: 50S-55S.
  • 12
    Bronowicki JP, Davis M, Flamm S, et al. Sustained virological response in prior peginterferon/ribavirin treatment failures after retreatment with boceprevir plus peginterferon and ribavirin: provide study interim results. J Hepatol 2012; Abstract 204.